CliffBio
biologic

Remicade

infliximab

Loss of exclusivityAugust 2010projected — 12-year biologic exclusivity estimate
CompanyJanssen Biotech →See this company's full patent-cliff portfolio

Drug detail

Brand nameRemicade
Active ingredientinfliximab
Strength100MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalAugust 1998
Marketing statusRx

More from Janssen Biotech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Remicade patent cliff — loss of exclusivity August 2010 | CliffBio